Biotie Therapies Corp., a drug development company, focuses on the development of drugs for neurodegenerative and psychiatric disorders primarily in Finland and the United States. Its products include Selincro (nalmefene), a dual-acting opioid system modulator that reduces alcohol consumption in alcohol dependent individuals; Tozadenant (SYN115), an oral, potent and selective adenosine A2a receptor antagonist for the treatment of Parkinson’s disease that is in Phase III development; and Nepicastat (SYN117) an orally administered inhibitor for the treatment for cocaine dependence, which has completed in Phase II trial. The company’s products also comprise BTT1023, a monoclonal antibody targeting Vascular Adhesion Protein 1 in Phase II development in fibrotic conditions and received orphan drug designation for the treatment of primary sclerosing cholangitis; and SYN120, an oral, potent, dual antagonist of the 5-HT6 and 5-HT2A receptors that has completed single and multiple ascending dose Phase I clinical studies and a Phase I positron emission tomography imaging study to determine therapeutic dose for subsequent Phase II studies. Biotie Therapies Corp. is based in Turku, Finland.
biotie therapies oyj (BTH1V:Helsinki)
Phone: 358 2274 8900
Fax: 358 2274 8910www.biotie.com
|No competitor information is available for BTH1V.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact BIOTIE THERAPIES OYJ, please visit www.biotie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.